Johnson & Johnson (JNJ) Change in Receivables (2009 - 2026)
Johnson & Johnson (JNJ) posted Change in Receivables of $1.4 billion for Q2 2026, up 127.23% sequentially from $595.0 million in Q1 2026, and little changed YoY from $1.4 billion in Q2 2025.
Johnson & Johnson (JNJ) Change in Receivables (2009 - 2026) Analysis & Trends
Johnson & Johnson has reported Change in Receivables for 18 years, with the latest figure at $1.4 billion in Q2 2026.
- Quarterly Change in Receivables changed 0.37% year-over-year to $1.4 billion in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $1.4 billion (down 5.31% YoY) and the FY2025 annual result came in at $1.8 billion, up 338.67% from the prior year.
- Change in Receivables improved to $1.4 billion in Q2 2026 per JNJ's latest filing, from $595.0 million in the prior quarter.
- Over five years, Change in Receivables peaked at $1.4 billion in Q2 2025 and troughed at -$853.0 million in Q4 2024.
- A 5-year average of $291.1 million and a median of $265.5 million in 2023 frame the typical range for Change in Receivables.
- The widest YoY moves for Change in Receivables: up 416.67% in 2024, down 275.77% in 2024.
- Over 5 years, Change in Receivables stood at $427.0 million in 2022, then tumbled by 153.16% to -$227.0 million in 2023, then slumped by 275.77% to -$853.0 million in 2024, then jumped by 54.16% to -$391.0 million in 2025, then surged by 445.78% to $1.4 billion in 2026.
- According to Business Quant data, Change in Receivables over the past three periods registered $1.4 billion, $595.0 million, and -$391.0 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 1.35 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 1.37 Bn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | - |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | - |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | - |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 1.09 Bn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 333.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | - |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | - |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 28, 2026 | 1.35 Bn |
| Jun 28, 2026 | 1.35 Bn |
| Mar 29, 2026 | 595.00 Mn |
| Mar 29, 2026 | 595.00 Mn |
| Dec 28, 2025 | -391.00 Mn |
| Dec 28, 2025 | -391.00 Mn |
| Sep 28, 2025 | -111.00 Mn |
| Sep 28, 2025 | -111.00 Mn |
| Jun 29, 2025 | 1.36 Bn |
| Jun 29, 2025 | 1.36 Bn |
| Mar 30, 2025 | 926.00 Mn |
| Mar 30, 2025 | 926.00 Mn |
| Dec 29, 2024 | -853.00 Mn |
| Dec 29, 2024 | -853.00 Mn |
| Sep 29, 2024 | 96.00 Mn |
| Sep 29, 2024 | 96.00 Mn |
| Jun 30, 2024 | 884.00 Mn |
| Jun 30, 2024 | 884.00 Mn |
| Mar 31, 2024 | 279.00 Mn |
| Mar 31, 2024 | 279.00 Mn |